Teva Pharma Posts Lower Q4 Earnings, FY23 Outlook Within Expectations
Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) Q4 sales reached $3.88 billion, shrinking 5% Y/Y, missing the consensus of $3.93 billion. The…
EXCLUSIVE: Risk Appetite On The Rise, TD Ameritrade’s IMX Climbs 3.36%
Each month, TD Ameritrade issues a proprietary data sample it calls the “investor movement index.”
Year Of Volatility: Stocks Exposed To Russia-Ukraine War See Big Gains/Losses
It's been one year since the world watched as Russian President Vladimir Putin mobilized over 100,000 troops along Ukraine's border, signaling a possible full-scale attack.
Roche Touts Positive Crovalimab Data From Late-Stage Study In Rare Blood Condition
Roche Holdings AG (OTC:RHHBY) has announced results from the global phase 3 COMMODORE 2 study, evaluating the efficacy and…
Barrick Gold Unlikely To Offer Rival Bid For Australia-Based Newcrest Mining Deal
Barrick Gold Corp (NYSE:GOLD) has denied a counterbid for Newcrest Mining (OTC: NCMGY) (OTC: NCMGF), eliminating what had seemed to be the most…
Apollo Weighs Buying Stake In Credit Suisse’s Investment Banking Unit
Apollo Global Management (NYSE: APO) is reportedly looking to buy a stake in Credit Suisse Group Inc's (NYSE: CS) revamped investment bank.
How Warren Buffett’s Fund Manager Turned $70K Into $264M: ‘In A Perfect World, Nobody Would Know About This’
Legendary investor Warren Buffett is widely considered one of the greatest investors of all time.
Big Pharma Bristol-Myers Returns $475M IL-12 Oncology Asset To Dragonfly
Bristol-Myers Squibb & Co (NYSE:BMY) has returned the exclusive rights to Dragonfly Therapeutics‘ IL-12 oncology candidate. In 2020, BMS handed out $475 million in…
Johnson & Johnson’s Drug Acquired Via Momenta Deal Shows Encouraging Data In Fetal Disorder
Janssen, a unit of Johnson & Johnson (NYSE:JNJ), announced topline results from the proof-of-concept Phase 2 open-label UNITY trial for…
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its ‘Incrementally Positive’
The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc’s (NASDAQ:BIIB) zuranolone for major depressive…